Detection and treatment of lung adenocarcinoma at pre-/minimally invasive stage: is it lead-time bias?
- 7 May 2022
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 148 (10) , 2717-2722
Abstract
Objectives This study investigates whether lead-time bias contributes to the excellent survival of AIS and MIA. Methods We enrolled patients with resected adenocarcinoma from 2008 to 2012. Age, sex, smoke history, surgical approach, radiological features, invasive stage and postoperative follow-up data were documented. 1:1 PSM was performed to balance the influence of sex and smoking status on survival. After matching, the average age of the two groups was compared to calculate the lead time of diagnosis. The gain in life years for adenocarcinoma diagnosed at pre-/minimally invasive stage was estimated by subtracting the “lead time” and “median survival year of IAC” from “the life expectancy of AIS/MIA patients” referring to the Centre for Health and Information. Results There were 124 AIS/MIA patients and 1148 IAC patients. The frequency of female and never-smoking patients in AIS/MIA group was much higher than that in IAC group. PSM analysis identified 124 patient pairs. No cancer-related death and recurrence were observed among AIS/MIA patients 5 years after surgery. For IAC patients, the 5-year disease-specific survival rate was 73.5% and the median survival is 13.5 years. The average age of AIS/MIA group and IAC group are 53.6 years and 58.2 years, respectively. The lead time between diagnosis of AIS/MIA and IAC is 4.6 years. Referring to the Centre for Health and Information, the life expectancy of patients with AIS/MIA diagnosed at 53.6 years old is 28.9 years. With adjustment for the lead time, the gain in life years for adenocarcinoma diagnosed at pre-/minimally invasive stage is 10.8 years. Conclusions With adjustment for the lead time between diagnosis of AIS/MIA and IAC, resecting lung adenocarcinoma at pre-/minimally invasive stage can improve life expectancy. The excellent survival of AIS/MIA is not lead-time bias.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81930073)
- Science and Technology Commission of Fengxian District, Shanghai Municipality (2017SHZDZX01)
- Shanghai Shenkang Hospital Development Center City Hospital Emerging Cutting-edge Technology Joint Research Project (SHDC12017102)
- Shanghai Municipal Health Commission Key Discipline Project (2017ZZ02025, 2017ZZ01019)
This publication has 28 references indexed in Scilit:
- Tumor invasiveness as defined by the newly proposed IASLC/ATS/ERS classification has prognostic significance for pathologic stage IA lung adenocarcinoma and can be predicted by radiologic parametersThe Journal of Thoracic and Cardiovascular Surgery, 2014
- Controversies in Lung Cancer ScreeningJournal of the American College of Radiology, 2013
- New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical TrialsJournal of Clinical Oncology, 2013
- Predictive Factors of Lymph Node Status in Small Peripheral Non-small Cell Lung Cancers: Tumor Histology is More ReliableAnnals of Surgical Oncology, 2012
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNew England Journal of Medicine, 2011
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung AdenocarcinomaJournal of Thoracic Oncology, 2011
- Stepwise progression of pulmonary adenocarcinoma—clinical and molecular implicationsCancer and Metastasis Reviews, 2010
- Lung Cancer Screening2010
- Basic Epidemiologic Methods for Cancer Investigations2007
- Cancer Screening2004